HealthKick Podcast: Dr Chris Behrenbruch on taking Telix Pharma to $1bn and the future of nuclear medicine

Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast.

In this episode Tim chats with Dr Chris Behrenbruch, bioscience entrepreneur and CEO of Telix Pharmaceuticals  (ASX:TLX).

Telix’s research and development pipeline currently centres around on unmet needs in cancer care, specifically in prostate, renal (kidney) and glioblastoma (brain) cancer.

The company is also focused on securing partnership and in-licensing opportunities to further expand its portfolio.

Telix appeared in a Stockhead article late last year following the announcement of initial trial results for its TLX101 molecularly targeted radiation treatment.

So tune in below to hear all things Telix Pharmaceuticals.